Next 10 |
home / stock / bbio / bbio articles
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage biopharmaceutical c...
Monday, BridgeBio Pharma Inc (NASDAQ:BBIO) and Bayer AG (OTC:BAYRY) (OTC:BAYZF) announced a partnership wherein BridgeBio grant...
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of Reliance Steel & Aluminum Co. (N...
PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage bio...
- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related ...
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 P...
Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic dise...
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in&nbs...
PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage bi...
News, Short Squeeze, Breakout and More Instantly...
BridgeBio Pharma Inc. Company Name:
BBIO Stock Symbol:
NYSE Market:
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional ...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capi...